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Abstract
Background: Fibrocytes are implicated in Idiopathic Pulmonary Fibrosis (IPF) pathogenesis and increased
proportions in the circulation are associated with poor prognosis. Upon tissue injury, fibrocytes migrate to the
affected organ. In IPF patients, circulating fibrocytes are increased especially during exacerbations, however
fibrocytes in the lungs have not been examined.
Therefore, we sought to evaluate if fibrocytes can be detected in IPF lungs and we compare percentages and
phenotypic characteristics of lung fibrocytes with circulating fibrocytes in IPF.
Methods: First we optimized flow cytometric detection circulating fibrocytes using a unique combination of intra-
and extra-cellular markers to establish a solid gating strategy. Next we analyzed lung fibrocytes in single cell
suspensions of explanted IPF and control lungs and compared characteristics and numbers with circulating
fibrocytes of IPF.
Results: Using a gating strategy for both circulating and lung fibrocytes, which excludes potentially contaminating
cell populations (e.g. neutrophils and different leukocyte subsets), we show that patients with IPF have increased
proportions of fibrocytes, not only in the circulation, but also in explanted end-stage IPF lungs. These lung
fibrocytes have increased surface expression of HLA-DR, increased intracellular collagen-1 expression, and also
altered forward and side scatter characteristics compared with their circulating counterparts.
Conclusions: These findings demonstrate that lung fibrocytes in IPF patients can be quantified and characterized
by flow cytometry. Lung fibrocytes have different characteristics than circulating fibrocytes and represent an
intermediate cell population between circulating fibrocytes and lung fibroblast. Therefore, more insight in their
phenotype might lead to specific therapeutic targeting in fibrotic lung diseases.
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Background
Fibrocytes are thought to be the precursors of fibroblasts
and were first described in an experimental skin wound
model in mice as bone marrow-derived cells producing
extracellular matrix proteins aiding wound healing [1].
Fibrocytes are derived from a common monocyte lineage
[2] and upon tissue injury, they migrate to the affected
organ in response to chemotactic factors, where they differ-
entiate into fibroblast-like cells. Next to differentiation into
(myo) fibrobalsts, fibrocytes are thought to display several
paracrine functions, including fibroblast activation, alterna-
tive macrophage-dependent and -independent inflamma-
tory processes, which all could lead to tissue remodeling
and fibrosis [3–7]. The contribution of fibrocytes to the
pathogenesis of fibrotic diseases and their potential use as a
biomarker in fibrotic lung diseases and pulmonary
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hypertension (PH) has investigated, as they correlate to dis-
ease progression and survival [8–11].
However, a uniform (gating) strategy to identify fibro-
cytes is lacking. It is generally accepted that the minim-
ally needed markers are CD45 (hematopoietic marker)
and intracellular collagen-1 [12–14]. Discrepancies in
opinion how to further accurately characterize fibrocytes
may originate from two possible problems. First, it is un-
clear whether other extracellular markers are really
needed, and if so, which ones would then be the most
optimal. Most often CD34 (hemopoietic stem cell
marker) and CXCR4 (C-X-C chemokine receptor 4),
which are expressed on almost all circulating fibrocytes,
are used. Secondly, there is no consensus whether circu-
lating fibrocytes are cells with high side scatter (SSC)
characteristics, a measure of cell granularity or internal
complexity. Most studies have shown that CD45+/
collagen-1+ fibrocytes represent a heterogeneous cell
population primarily found in the polymorphonuclear
(PMN) cell fraction with high SSC [8, 9, 13–15]. In
contrast, others have demonstrated that circulating
fibrocytes share side scatter characteristics comparable
with blood mononuclear cell fraction based on cell
sorting experiments [16, 17]. As a consequence, it is
unclear whether differences in SSC represent different
subpopulations, different stages of development or
whether this reflect methodological issues.
Lung fibrocytes may hold promise in a better under-
standing of fibrocyte biology, as they have become fully
differentiated effector cells and their paracrine and in-
flammatory function have taken shape.
Increased CD45+/collagen-1+ fibrocytes have been
found in bronchoalveolar lavage (BAL) of IPF patients
[18]. However, whether lung fibrocytes can be detected
in IPF lung tissue homogenates using flow cytometry is
currently unknown.
In our study, we propose a gating strategy and pheno-
typic staining for a more specific selection of circulating
and lung fibrocytes and compare proportions and pheno-
typical characteristics of lung fibrocytes in IPF lung tissue
with circulating fibrocytes in patients with IPF. Reliably
identification of circulating and lung fibrocytes could be
of great value of developing new therapies that target cir-
culating and lung fibrocytes in IPF.
Materials and methods
Study design and subjects
Human lung tissue was collected from patients with end-
stage IPF undergoing lung transplantation. As a control,
lung tissue was obtained from long volume reduction pro-
cedures during lung transplantation upon size mismatch
of oversized donor lungs or residual material obtained
during lung surgery for pulmonary tumors. Healthy re-
sidual tissue was obtained at least > 3 cm from the tumor
and only patients with a normal pulmonary function test
(PFT) or mild airflow obstruction (Gold 1) were selected.
All patient and healthy subject characteristics are shown
in Additional file 1.
The Medical Ethical Committee of the Erasmus MC
Rotterdam approved this study (METC 2012–512). In-
formed consent was obtained from every participant and
healthy control (HC) before collection of blood samples.
The diagnosis of pulmonary hypertension or pulmonary
fibrosis was conform the current diagnostic guidelines of
the ATS/ERS [19–21].
Blood processing
Blood samples were collected in EDTA tubes (BD Vacu-
tainer K2E). Peripheral blood mononuclear cells (PBMC)
and total white blood cells were obtained according to
standard protocols. In short, PBMC were obtained using
the Ficoll separation technique and whole white blood
cells with the simple Pasteur pipette tube technique after
spinning samples at 1000 x g as previously described
[22]. Red blood cells were lysed using osmotic lysis buf-
fer (8.3% NH4CL, 1% KHCO3, and 0.04% NA2EDTA in
Milli-Q). Upon isolation, PBMC and total white blood
cells were resuspended in 0.1% BSA + 2 mM EDTA in
PBS and immediately processed for flow cytometry and
fluorescence-activated cell sorting (FACS). Isolated PBMC
or total white blood cells, not used for direct flow cytome-
try or FACS, were aliquoted and cryopreserved in
complete RPMI (RPMI medium 1640 + glutaMax, Life
Technologies) with 10% DMSO (Sigma), 40% Fetal calf
Serum (FCS) and stored at − 196 °C until thawing.
Lung tissue processing
Fresh lung tissue was stored in cold PBS and processed
within 24 h following lung transplantation or resection.
Lung tissue was processed for isolation of single cell sus-
pensions described in section “preparation of single cell
suspensions”. Furthermore, peripheral lung tissue was
frozen and stored at − 80 °C until further use.
Preparation of single cell suspensions
Lung resection specimens were rinsed with PBS to re-
move residual blood. After mincing the lung, specimens
were enzymatically digested in digestion medium (20 ml
HBSS (Life Technologies, 14,170–088) with 10μg Liber-
ase (Roche, Liberase™, research grade) and 40 Units of
DNA-se (Roche, DNase I recombinant, RNase-free)) for
30 min in a humidified incubator at 37 °C while gently
shaking the samples. The remaining cell debris was re-
moved by passing the cells through a 100 μm-diameter
disposable cell mesh filter. The cells were washed in
RPMI with 5% FCS and centrifuged for 10 min at a
speed of 400×g. Samples were subjected to RBC lysis,
washed and counted. Finally, samples were aliquoted
Heukels et al. Respiratory Research  (2018) 19:90 Page 2 of 12
and cryopreserved in complete RPMI with 10% DMSO
(Sigma), and 40% Fetal Calf Serum (FCS) and stored at
− 196 °C.
Human fibrocyte and human fibroblast culture
Human fibrocytes were cultured from peripheral blood as
previously described [7], with some modifications. Briefly,
following Ficoll density centrifugation, 2 × 10^5 PBMCs
were plated into culture-slides (sigma, C7182, 0.8 cm2/
well) in complete culture medium (Dulbecco’s modified
Eagle’s medium) (DMEM) supplemented with 20% fetal
calf serum, 2 mM L-glutamine, 100 U/mL of penicillin,
100 mg/mL of streptomycin) (Life Technologies, Grand
Island, NY) at 37 °C and 5% CO2. After 3 days, non-
adherent cells were aspirated and discarded and fresh
medium was applied. Following 10–14 days of culture,
slides were washed three times with ice-cold PBS and the
chambers were removed from the glass. Normal human
lung fibroblasts (NHLF) were also cultured on culture
slides (50,000 NHLF/well) in complete culture medium.
NHLF were donated from the Laboratory of the Univer-
sity of Virginia (School of Medicine, Charlottesville, VA,
USA.) After 2–3 days non-adherent NHLF were aspirated
and discarded. Subsequently, the cultured NHLF were
washed with ice-cold PBS, dried and and processed simi-
larly to the cultured human fibrocytes.
Flow cytometry and FACS staining
Freshly isolated PBMCs and total white blood cells were
stained for extra- and intracellular markers using the fol-
lowing antibodies: CD45-V450 (HI30), CD56-Af488
(B159 RUO), CD15-PE (HI98), CD16-PerCP-Cy5.5
(3G8), HLA-DR-BV711 (G46–6), CXCR4 (CD184)-Pe-
Cy7 (12G-5) (BD Biosciences), strep-APC-eF780, CD3-
FITC (UCHT1), CD19-FITC (HIB19) (eBiosciences),
Collagen-1-Biotin conjugated Bio (Rockland, 600–406-
103), CD14-PE-Texas Red (Tuk4) (Invitrogen). To con-
trol for non-specific labeling Rabbit IgG-Biotin conju-
gated (Rockland, 011–0602) was used. For the cell
sorting experiments, the same extra-cellular antibodies
were used, except for HLA-DR: HLA-DR-APC (G46–6)
(BD Biosciences).
Since macrophages in lung single cell suspensions have
high auto fluorescence, we did not use fluorochromes
FITC and Alexa Fluor 488 in the staining and used the
following antibodies: CD3-BV711 (UCHT1), CD19-
BV786 (J25C1), CD56-BV605 (NCAM16.2) (BD Biosci-
ences). Fixable Viability Dye eFluor 506 (eBiosciences)
was applied as a live-dead marker for flow cytometry ex-
periments and 4′,6-diamidino-2-phenylindole (DAPI)
(Invitrogen, Molecular Probes) was used as live-dead
marker for the cell sorting experiments. In short, cells
were incubated in FACS buffer (PBS, 0.25% BSA, 0.
5 mM EDTA, 0.05% NaN3 sodium azide) with
fluorescent antibodies for 30 min at 4 °C using methods
recommended by the manufacturers. Of note, extra-
cellular CXCR4-Pe-Cy7 staining was performed separ-
ately in MACS buffer (0.5% BSA + 2 mM EDTA in PBS).
After fixation and permeabilization (BD Cytofix/Cyto-
perm kit, 554,714), cells were incubated with the bio-
tinylated Collagen-1 antibody or Isotype control in
permeabilization buffer for 30 min at 4 °C. Biotinylated
antibodies were visualized with streptavidin-APC-eF780.
Cells were measured on a either a LSRII or a FACS
Aria™ IIu Flow cytometer (both BD Biosciences). We an-
alyzed a minimum of 200,000 alive cells for blood sam-
ples and 100,000 alive cells for the lung tissue samples
for cytometric analysis. Data was analyzed by FACS
Flow-Jo software.
Cytospin
Sorted cells were washed in PBS. Cytospins were made
using a cytocentrifuge and 50,000 cells were added per
spot. Slides were air-dried and stored at − 80 °C in a
watertight box until further use. Immunocytochemistry
was performed within 4 weeks after storing at − 80 °C.
Immunocytochemistry
Cytospin-slides were fixed in 100% acetone at room
temperature for 15 min. For the collagen-1 staining,
slides were pre-incubated with 10% normal goat serum
(Sigma, G9023) in block buffer (1% Blocking Reagent,
Roche, in PBS according to the manufacturer’s protocol)
for 30 min. After rinsing with PBS, slides were incubated
for 60 min with mouse anti-human collagen-1 (Abcam,
ab6308, 1:2000) or Isotype control in block buffer. As
second (goat anti-mouse antibody biotin-labeled) and
third antibody (streptavidin, alkaline phosphatase (AP)
conjugate) we used the Link-Label kit from Biogenex
(link: HK-325-UM, label HK321-UK) according to the
manufacturer’s protocol. To detect the collagen-1 posi-
tive cells we used New Fuchsin Alkaline Phosphatase
Substrate Solution (0.01% New Fuchsin, 0.02% Sodium
Nitrite, 0.03% Naphthol AS-BI Phosphate, 1 mM Lev-
amisole, in 0.2 M Tris-HCl, pH 8.5). Cells were counter-
stained with hematoxylin (Sigma, Gill No. 3), dried and
mounted in Vecta Mount (Vector, Burlingame, CA,
USA). For CD15 detection we used the same protocol,
but with different antibodies; slides were pre-incubated
with normal rabbit serum (Sigma, R9133) and subse-
quently stained with mouse anti-human CD15-FITC
(BD Biosciences, HI98) or isotype control and rat anti-
FITC AP conjugate (Sigma, A4843).
Statistics
Statistical analysis was performed using IBM SPSS Statis-
tics 21 and GraphPad Prism 6 software. When evaluating
differences in continuous variables between multiple
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independent groups, the Kruskal-Wallis test was used. For
calculating the level of significance of differences between
groups we used the Mann-Whitney U test. Correlation co-
efficients were calculated using Spearman’s rank method.
P values < 0.05 were considered significant. Flow cytome-
try data is either represented as percentage population or
as mean fluorescence intensity (MFI).
Results
Circulating CD45+/Col-1+ fibrocytes may be contaminated
with polymorphonuclear leukocytes
Since discrepancies have been reported about fibrocytes
concerning their granularity and/or internal complexity,
we first evaluated SSC characteristics of fibrocytes iden-
tified based on CD45 and collagen-1 (Col-1) expression.
Fibrocytes were detected using the gating strategy shown
in Fig. 1a. Col-1 expression was based on the control
isotype staining. Circulating CD45+/Col-1+ fibrocytes
represented a heterogeneous cell population based on
SSC and have predominantly a high SCC (Fig. 1b)
Because SSC-high cells contain polymorphonuclear cells,
such as neutrophils, we examined the adhesion molecule
CD15, which is expressed on circulating neutrophils
[23]. The CD45+/Col1+ cells showed a high extracellular
expression level of CD15 (Fig. 1c). To investigate
whether this population could be contaminated with
neutrophils, we isolated circulating CD45+/Col-1+ cells
based on extracellular markers (sort strategy shown in
Additional file 2) and analyzed these cells with
immunocytochemistry (Fig. 1d). Almost all cells (98,6,
95% CI 97,9–99,2) in the flowcymetric enriched CD45+/
Col-1+ population were negative for collagen-1 and posi-
tive for CD15 with immunocytochemistry, whereas cul-
tured fibrocytes (Fig. 1d) and fibroblasts (Additional file 3)
were positively stained for collagen-1 and negative for
CD15. Additionally, all cells in the enriched CD45+/Col-
1+ group had a multi-lobulated shaped nucleus. We also
found a significant correlation between circulating
CD45+/Col-1+ cells and neutrophils (R = 0.39, p = 0.006)
(Additional file 4).
In conclusion, our data show that PMN-leukocytes
and especially neutrophils contaminate fibrocyte iden-
tification when using only CD45 and collagen-1 as
identification markers. Consequently percentages of




Fig. 1 Circulating CD45+/Col-1+ fibrocytes are contaminated with polymorphonuclear leukocytes. a Representative gating strategy for
identification of circulating CD45+/Collagen-1+ fibrocytes from PBMCs. Isotype control for collagen-1 (Col-1) was used to set the gate for Col-1+
cells within alive CD45+ cells. Red cells are CD45+Col-1+. b FSC and SSC characteristics of CD45+/Col-1+ cells (in red) compared to all alive cells
(blue) showing that most CD45+/Col-1+ cells are found in the polymorphonuclear leukocytes fraction. c Histogram overlay showing surface
expression of CD15 assessed by flow cytometry on CD45+/Col-1+ cells (red), CD14+ monocytes (black) and T cells (gray). d CD45+/Col-1+ cell
enriched fraction and PBMC cultured fibrocytes were analyzed with immunocytochemistry (ICC) for CD15 and collagen-1 expression. Magnification
for all ICC figures was 200× and sections were counterstained with hematoxylin. This is representative of 7 experimentsCD14+ Mo= CD14+
monocytes, PBMC= peripheral blood mononuclear cells, FSC = forward scatter, SSC = side scatter.
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Identification and characterization of lung fibrocytes in
IPF lungs
As neutrophils hamper the identification of fibrocytes in
peripheral blood, we developed a strategy to selectively
identify fibrocytes. Since circulating fibrocytes are a pu-
tative source for fibroblastic foci, a hallmark of IPF, we
used IPF lungs to test our gating strategy. Lung fibro-
cytes in IPF lungs initially maintain CD45 expression
and their presence has been previously confirmed with
immunofluorescence [11, 24]. We obtained single-cell
suspensions of explanted IPF lungs (n = 3). As a control
we used healthy lung tissue from volume reduction pro-
cedures during lung transplantation or residual material
of patients who underwent a lobectomy for lung cancer,
hereafter called control lungs (n = 4).
All explanted lungs of IPF patients used in this study
were reviewed by a pathologist and fulfilled the criteria for
an usual interstitial pneumonia (UIP) pattern (Fig. 2a). We
next evaluated whether we could selectively identify fibro-
cytes after exclusion of neutrophils, T cells, NK cells, and B
cells. Using this strategy, we could distinguish a fibrocyte
population expressing CD45, CXCR4 and intracellular
collagen-1 in both IPF lungs and control lungs (Fig. 2b).
Fibrocytes express CD45, CXCR4 and CD34 and intra-
cellular collagen-1 and are generally believed to mature
from a subpopulation of CD14+ mononuclear cells [25].
Figure 2c shows the expression level of these markers
and HLA-DR, CD14, CD16 on lung fibrocytes
(CD45+CD3−CD19−CD56−CD15−CXCR4+Col-1+). CD45
expression on lung fibrocytes was slightly lower than on
T-cells and CD14+ monocytes. As expected, collagen-1
and CXCR4 were clearly expressed by lung fibrocytes
compared to CD14+ monocytes and T cells. CD34, a
commonly used progenitor cell marker, is expressed on
fibrocytes when they have entered the lungs. HLA-DR
expression on lung tissue-resident fibrocytes is similar to
CD14+ monocytes and higher compared to T cells of the
same donor. Tissue-resident fibrocytes showed an inter-
mediate expression of CD14 (expression level between
CD14+ monocytes and T cells, which are CD14 nega-
tive) and relatively low expression of CD16.
In conclusion, lung fibrocytes can be detected in lung
single cell suspension after exclusion of neutrophils, T
cells, NK cells and B cells. Lung fibrocytes express known
fibrocyte surface markers such as CD34, CD45, and
CXCR4, and intracellular marker Col-1, suggesting that
they have just entered the lung tissue and have not differ-
entiated into myofibroblasts yet. The high expression by
HLA-DR of lung fibrocytes suggests that they have a po-
tential role in antigen presentation.
Detailed identification of circulating fibrocytes
Having shown that fibrocytes can be reliably detected in
lung single-cell suspensions after exclusion of neutrophils
and lymphocytes, we hypothesized that this would also be
applicable for the detection of circulating fibrocytes. Next
to IPF patients, we investigated fibrocytes in pulmonary
hypertension (PH) patients, as elevated number in the per-
iphery have been observed before [10]. We examined fresh
PBMC of IPF patients (n = 5), PH patients (n = 4) and
healthy controls (HC)(n = 4). Patient characteristics are
detailed in Additional file 1: Table S1.
A representative dot-plot of the gating strategy to
identify circulating fibrocytes (CD45+lin-CD15-CXCR4+-
Col-1+-cells) is shown in Fig. 3a. (Lineage mix contains:
CD3, CD19, and CD56) A well-defined population of
circulating fibrocytes was identified in PBMC fractions
of HC, IPF and PH patients.
Next, we investigated the expression profile of circulat-
ing fibrocytes. Circulating fibrocytes expressed high levels
of collagen-1, CXCR4 and CD34 and lower levels of CD45
compared with CD14+ classical monocytes and T cells
(Fig. 3b). HLA-DR expression on circulating fibrocytes
was comparable to HLA-DR expression on T cells,
whereas CD14+ classical monocytes contained cells with
high, low, and intermediate HLA-DR expression. Interest-
ingly, the majority of circulating fibrocytes have a low ex-
pression of CD14 and only a small proportion (11,3 95%
CI 9,7–13,0%) expressed CD14 comparable to classical
monocytes. CD16 expression on circulating fibrocytes was
lower compared to classical monocytes and slightly higher
than T cells of the same donor.
In conclusion, these data show that circulating fibro-
cytes can be detected after exclusion of neutrophils, T, B
and NK cells, and express markers in common with lung
fibrocytes. HLA-DR and CD16 expression are low on
circulating fibrocytes and only a small fraction expresses
high levels of CD14.
Quantification of fibrocyte numbers is independent of
leukocyte isolation strategy used
Since the presence of neutrophils hampers the detection
of fibrocytes and to confirm the specificity of our stain-
ing, we compared two common leukocyte isolation tech-
niques. We compared the Ficoll separation technique to
isolate PBMCs to remove PMN-leukocytes, and the sim-
ple Pasteur pipette tube technique to isolated all white
blood cells. We analyzed paired total white blood cells
and PBMCs on the same day as blood withdrawal of 9
patients (4 IPF patients and 5 PH patients) and 5 healthy
controls. The absolute number of circulating fibrocytes
(CD45 + Lin-CD15-CXCR4 + Col-1+) per milliliter (ml)
blood was not different between the two leukocyte isola-
tion techniques (2,5 × 103 (95% CI -0,4 × 103–9,0 × 103)
(Pasteur pipette technique) versus 1,8 × 103 (95% CI 1,1 ×
103–1,7 × 103)(Ficoll separation technique)) (Fig. 4a). As
expected, the proportions of circulating fibrocytes from
CD45+ cells was relatively higher in PBMC samples than
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in whole blood samples, because the Ficoll technique
eliminated most PMN-leukocytes (Fig. 4b). The lack of
difference in fibrocytes percentages in this figure between
groups of patients and controls is probably the result of
the low number of patients used for this experiment.
In conclusion, our strategy to identify fibrocytes is reli-
able, irrespective of which leukocyte isolation technique
is used, for the quantification of absolute numbers of cir-
culating fibrocytes.
Comparison of circulating fibrocytes with lung fibrocytes
Upon tissue injury, fibrocytes migrate to target organs
and mature in (myo) fibroblasts and participate in tissue
remodelling and fibrosis. It is unclear if circulating
fibrocytes become more activated, or modulate surface
markers (e.g. CD45, CD34 or CXCR4), or upregulate
intracellular collagen-1 when entering the lung. There-
fore we simultaneously compared the expression levels
of these markers between circulating and tissue-
resident fibrocytes.
Collagen-1 expression in fibrocytes did not differ be-
tween IPF/(IPAH) patients and (healthy) controls in ei-
ther lung cell suspensions or PBMCs (Fig. 5a, left). The
collagen-1 expression in lung fibrocytes was significantly
higher compared with circulating fibrocytes in patients




Fig. 2 Identification and characterization of lung fibrocytes in IPF lungs. a Representative histological picture of an explanted end-stage IPF lung
showing (left): a usual interstitial pneumonia (UIP) pattern with (*) a fibroblast focus with overlying reactive epithelium and (right): (**) area of
completely fibrotic remodeled lung tissue with cyst formation and bronchiolisation, amounting to honeycombing. Magnification 20× (left) and
5× (right). b Representative gating strategy for lung fibrocytes (CD45+CD15−CD3−CD19−CD56−CXCR4+Col-1+-cells) in explanted IPF lungs (n = 3
bottom) and control lungs (HC, top) (n = 4). Single cell suspensions were thawed and alive viable cells were further analyzed. Lung fibrocytes are
present in the CD45+ cell population. Contaminating and unwanted CD15+ neutrophils, CD3+ T cells, CD19+ B cells and CD56+ NK-cells were
sequentially excluded. Isotype control for Col-1 was used to set the gate for Col-1+ cells. c Representative histogram overlay showing expression
levels depicted as MFI of indicated markers assessed with flow cytometry of lung fibrocytes (red), T cells (gray) and CD14+ monocytes (black).
CD14+ Mo = CD14+ monocytes, MFI = mean fluorescence intensity
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ab
Fig. 3 Characterization of circulating fibrocytes in IPF and PH patients. a Representative gating strategy for the detection of circulating fibrocytes
(CD45+CD15−Lin−CXCR4+Col-1+-cells) in freshly analyzed PBMCs of heathy controls (n = 5), PH patients (n = 5) and IPF patients (n = 4). The lineage
mix includes markers CD3, CD19 and CD56 to exclude T-cells, B-cells and NK-cells. b Representative histogram overlay showing expression levels
depicted as MFI of indicated markers assessed with flow cytometry of circulating fibrocytes (red), T cells (gray) and CD14+ monocytes (black)
a b
Fig. 4 The total number of circulating fibrocytes is unaffected by the leukocyte isolation strategy used. a Total number of circulating fibrocytes
(defined as CD45+lin−CD15−CXCR4+Col-1+ cells) per ml blood using two common leukocyte isolation techniques, e.g. the simple Pasteur pipette
tube technique to isolate all white blood cells and Ficoll separation technique to isolate PBMCs. For this experiment we analyzed paired total
white blood cells and PBMCs on the same day as blood withdrawal of 9 patients (4 IPF patients (black) and 5 PH patients (purple)) and 5 healthy
controls (green). b Percentage of fibrocytes (of CD45+ cells) in the same patients after isolating all white blood cells (gray) and PBMCs (black).
Data are depicted as median and interquartile
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Expression of HLA-DR was similar between IPF/IPAH
patients and controls (Fig. 5a, right). Tissue-resident
fibrocytes showed a significantly increased expression of
HLA-DR compared to circulating fibrocytes. CD34 and
CXCR4 expression between circulating and tissue-
resident fibrocytes did not differ (data not shown).
To examine the size and complexity of circulating and
lung fibrocytes, we examined SSC and FSC of the fibro-
cytes selected as shown in Figs. 2b and 3a. Circulating
fibrocytes had FSC and SSC characteristics comparable
to monocytes. In the lung, both FSC and SSC of lung
fibrocytes were increased compared to circulating fibro-
cytes (Fig. 5b). The variation in FSC and SSC character-
istics of lung fibrocytes could be the result of differences
in granularity, activation status and collagen content.
In conclusion, these data show that lung tissue-
resident fibrocytes have increased expression levels of
HLA-DR and collagen-1 and also gain size and internal
complexity compared with their circulating counterpart.
No differences were observed within a compartment be-
tween controls or patients with IPF or IPAH, which may
suggest an important role of the local environment in
lungs on fibrocyte development.
Increased proportions of fibrocytes in the lungs and
circulation of patients with IPF
Having shown that our gating strategy to detect fibrocytes
is reliable and specific, we wanted to apply this technique
in a larger, clinically relevant, cohort of PH and IPF pa-
tients, in which increased percentages of circulating fibro-
cytes have been described before [8, 10, 12]. To minimize
variability in fibrocytes due to heterogeneity in etiology of
PH, only patients with idiopathic arterial pulmonary hyper-
tension (IPAH) were examined. We thus determined fibro-
cyte percentages in PBMCs of patients with IPF (n = 14),
IPAH (n = 10), and HC (n = 10).
Circulating fibrocytes are significantly increased in pa-
tients with IPF compared with control samples (p < 0.01)
(Fig. 6a and Additional file 5). The average percentage of
circulating fibrocytes in IPF patients was 0.25% (95% CI
0.17–0.33) of all CD45+ cells, compared with 0.10% in
HC (95% CI 0.03–0.17). The percentage of circulating
fibrocytes in IPAH patient was 0.18% (95% CI 0.08–0.22)
and not increased compared with HC (p = 0.14).
In line with previous literature, we have shown that
circulating fibrocytes are increased in patients with IPF.
We next evaluated whether lung fibrocytes would also
a
b
Fig. 5 Comparison of circulating fibrocytes with lung fibrocytes. a Intracellular Collagen-1 and surface HLA-DR expression analyzed with flow cytometry
and depicted as MFI. For this experiment, we used frozen PBMC of 10 HC, 10 IPF patients and 10 IPAH patients and frozen single cells suspensions of 5
control lungs and 5 explanted IPF lungs. b representative dot-plot of the FCS and SSC characteristics assessed with flow cytometry of circulating and
lung fibrocytes (red dots) in the circulation (left panel) and explanted IPF-lung (right panel). Nonparametric two-tailed Mann-Whitney test was used.
Data are depicted as median and interquartile. * P < 0.05 *** P < 0.001IPAH = idiopathic pulmonary arterial hypertension, PMN= polymorphonuclear.
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be increased in lungs of patients with IPF (n = 8) and
compared them to control lungs (n = 9) (Fig. 6b).
Clinical characteristics of these patients are shown in
Additional file 1.
Indeed, the percentage of lung fibrocytes in IPF lungs
was 2,6% (95% CI -0.8-5.9) of all CD45+ cells, which was
increased (p = 0.002) compared with control lungs (0.7%,
(95% CI 0.02–1,3%)).
Collectively, these data show that patients with IPF
have increased proportions of fibrocytes, not only in the
circulation, but also in the lungs at end-stage disease.
Discussion
To our knowledge, this is the first time that lung fibro-
cytes in IPF lung tissue homogenates is assessed by flow
cytometry. We have shown that lung fibrocytes are ele-
vated in IPF lungs and express higher levels of HLA-DR
and collagen-1 and gain size and internal complexity com-
pared with circulating fibrocytes. We have used a reliable
gating strategy, which excludes disruptive cell populations,
and especially granulocytes, for a specific identification of
circulating and lung fibrocytes.
Identifying circulating fibrocytes using flow cytometry
is challenging since no uniform gating strategy exists,
leading to a high variability in circulating fibrocyte num-
bers in various reports. Circulating fibrocytes are bone
marrow-derived monocyte-like cells capable of produ-
cing components of the extra-cellular matrix, and there-
fore at least CD45 and intracellular Collagen-1 should
be used to identify circulating fibrocytes. In addition,
CD34 and a variety of chemokine receptors have been
used to identify subtypes of circulating fibrocytes, most
notably CXCR4, CCR7, and CCR2. In the present study,
we have shown that CXCR4 is equally expressed on lung
and circulating fibrocytes irrespective of underlying
disease. Most circulating fibrocytes also express CD34
[5, 16, 26]. We have shown that lung fibrocytes also ex-
presses CD34. CD34 binds to L-selectin and in L-
selectin KO-mice fibrosis induction is hampered in the
bleomycin exposure model of lung fibrosis [27]. This
suggest that CD34 might be needed for circulating fi-
brocytes to enter the lung tissue via L-selectin expressed
on activated endothelial cells. It is unclear if or at what
point CD34 may be downregulated in vivo, as
Andersson-Sjoland and colleagues have shown by dem-
onstrating that mature alfa-SMA positive fibrocytes in
IPF lungs still express CD34 [24]. In vitro, CCR7 expres-
sion correlates with increased migration of circulating
fibrocytes and TGF-β production [28]. The CCR2-CCL2
axis promotes fibrocyte recruitment and induces their
differentiation into (myo) fibroblasts [29, 30]. Therefore,
it is believed that these chemokines receptor-bearing
fibrocytes may represent a more activated subtype, how-
ever expression levels of these markers varies between
different diseases and the majority of fibrocytes do not
express CCR2 and CCR7 [6, 7, 28, 31, 32]. The gating
strategy described here could be used for reliable deter-
mination of these homing receptors and other markers
of interest.
Our study has shown that the circulating fibrocyte
pool is contaminated with granulocytes when employing
a gating strategy based on CD45 and collagen-1 alone.
Contamination of granulocytes is most likely the result
of non-specific binding of collagen-1 antibody to granu-
locytes. Neutrophils, the most prevalent granulocytes,
express a variety of collagen receptors and play an
ba
Fig. 6 Circulating and Lung fibrocyte numbers in patients with IPF and idiopathic pulmonary hypertension (IPAH). a Percentage of circulating
fibrocytes of CD45+ cells in frozen PBMC of HC, patients with IPF and patients with IPAH. b Percentage of lung fibrocytes of CD45+ cells in
frozen single cell suspensions of control lungs (n = 9) or end-stage explanted IPF lungs (n = 8). Nonparametric two-tailed Mann-Whitney test was
used. Data are depicted as median and interquartile. ** P < 0.01
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important role in collagen breakdown. However, to our
knowledge there are no reports of collagen-containing
neutrophils, suggesting that antibody binding is non-
specific [33]. It is well known that Fc Receptors on gran-
ulocytes can cause nonspecific, false-positive antibody
staining, even in the presence of specific blocking re-
agents [34]. Presumably, in very ill patients granulocytes
could express more Fc-receptors compared with healthy
subjects [35, 36]. Additionally, we observed that circulat-
ing fibrocytes had similar FSC and SSC characteristics
compared to monocytes. Therefore, we strongly advo-
cate the use of markers that exclude granulocytes in
current gating protocols to identify fibrocytes.
In line with previous reports [8, 12], we found in-
creased percentages of circulating fibrocytes in patients
with IPF, but not in patients with IPAH. Yeager and col-
leagues described increased percentages of circulating
fibrocytes in children with idiopathic or hereditable PH
[10]. It is conceivable that in our relative small sample
size, the extent of tissue remodeling or fibrosis in IPAH
patients is relatively too low to pick up differences in cir-
culating fibrocytes. Therefore, a larger cohort of patients
is probably needed to investigate if circulating fibrocytes
are also elevated in adults with IPAH.
The proportions of circulating fibrocytes we describe
after eliminating disruptive cell populations is much
lower than previously reported. Like macrophages, fibro-
cytes are monocyte-derived and their development into
an effector cell is primarily established outside the circu-
lation and depends on local tissue environment [37]. It
is though that the monocyte-fibrocyte pathway may be
similar and that the majority of fibrocytes is present in
target organs. Indeed, we have shown that tissue-
resident fibrocytes can be identified in IPF lungs using
flow cytometry and that they make up a greater propor-
tion of the CD45+ cell compartment compared with
their circulating counterpart. These lung fibrocytes
express high levels of collagen-1 compared to the cir-
culating fibrocytes, which makes the collagen-1 staining
more robust. HLA-DR expression is also upregulated in
lung fibrocytes compared to circulating fibrocytes. As
HLA-DR molecules can provoke or suppress T-
(helper)-cell responses and are upregulated in response
to signaling, the increased expression may point toward
antigen-presentation or cross talk with local T cells in
vivo. It has also been shown that cultured fibrocytes ex-
press all the necessary costimulatory molecules for
antigen-presentation, that they are potent stimulators
of naive T-cells and induce a Th2 cytokine response in
vitro [38, 39].
Collectively, this gating strategy holds great potential
in investigating lung fibrocytes in more detail. This
method could replace experiments on artificially cul-
tured fibrocytes and allow for direct investigation of the
role of lung fibrocytes in tissue remodeling and fibrosis
in its target organ.
Conclusion
Using a gating strategy that excludes possible contaminat-
ing cell populations, we show that lung fibrocytes in IPF
lungs can be assessed by flow cytometry and that their
phenotype differs from circulating fibrocytes. This new ap-
proach could be interesting for scientists investigating the
fascinating role of fibrocytes in disease pathogenesis or
their potential as a biomarker and therapeutic target.
Additional files
Additional file 1: Characteristics of patients and the healthy subjects
used for experiments. Data are mean ± standard deviation, unless
indicated otherwise. a 1 patient with chronic thromboembolic PH and 4
patients with PH secondary to an auto-immune disease. b 6 patients with
IPF, 3 patients with UIP pattern secondary to extrinsic allergic alveolitis, 2
patients with an non-specific interstitial pneumonia and 1 patient with
anti-synthetase syndrome. c Mean FVC/FEV1 ratio = 0.71 (2 out of 9 had
an obstructive pulmonary function test, both classified as GOLD A). d
Assessed by right heart catheterization or suspected with
echocardiography. IPF = idiopathic pulmonary fibrosis, IPAH = idiopathic
pulmonary arterial hypertension, FVC = forced vital capacity, TLCO =
diffusing capacity for carbon monoxide, PAP = pulmonary arterial
pressure, RAP = right atrium pressure, Svo2 =mixed venous saturation,
PDE5i = phosphodiesterase type 5 inhibitor, ERA = endothelin receptor
antagonist, Pros-A = prostacyclin agonist (DOCX 22 kb)
Additional file 2: Sort strategy for CD45+/Col-1+ cells. (A) The
conventional strategy with the CD45+/Col-1+ cells in red. (B) Position of
the same fibrocytes when employing a gating strategy based on
additional extracellular markers. The sort strategy is based on extracellular
markers and with some modifications previously published [16] (of note:
for our research question we did not exclude SSChi cells). CD45+ cells
were analyzed for HLA-DR expression and lineage markers to exclude B-
cells (CD19), NK cells (CD56) and T-cells (CD3). Lineage negative cells
were plotted as CD14 versus CD16 to create a distinct group of cells
enriched for CD45+/Col-1+ cells (red box). (PDF 75 kb)
Additional file 3: Complete overview collagen-1 and CD15 staining on
CD45+/Col-1+ cells and controls. Immunocytochemical images of
cultured fibroblasts, cultured fibrocytes, sorted classical monocytes and
sorted CD45+/Col-1+ cells. Indicated cells were stained with Collagen-1 or
isotype control (rabbit IgG) and CD15. As a control for CD15 we used a
buffy coat, nicely showing positive granulocytes next to negative lym-
phocytes. Magnification for all images was 100×. (PDF 1282 kb)
Additional file 4: Correlation circulating CD45+/Col-1+ fibrocytes and
granulocytes. For this experiment we analyzed paired total white blood
cells (open dots) and PBMCs (black dots) on the same day as blood
withdrawal of 9 patients (4 IPF patients and 5 PH patients). Correlation
coefficients were calculated using Spearman’s rank method. (PDF 102 kb)
Additional file 5: Circulating fibrocyte numbers in patients with IPF and
idiopathic pulmonary hypertension (IPAH). (A) Absolute numbers of
circulating fibrocytes per ml blood in frozen PBMC of HC, patients with
IPF and patients with IPAH. ** P < 0.01 (PDF 91 kb)
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PNM: polymorphonuclear; SSC: side scatter
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